BUSINESS
Chugai Files Gene Panel Test for Use as Companion Diagnostic to Entrectinib
Chugai Pharmaceutical said on January 18 that it has filed for the expanded use of “FoundationOne CDx Cancer Genomic Profile,” a next-generation sequencing based program, in Japan to include its use as a companion diagnostic to the ROS1/TRK inhibitor entrectinib.…
To read the full story
Related Article
- Chugai Files for Gene Test for Companion Diagnostic to Lynparza
April 1, 2019
- Entrectinib Filed in Japan for ROS1 Lung Cancer: Chugai
March 18, 2019
BUSINESS
- FDA Extends Review of Capricor’s DMD Cell Therapy by 3 Months
August 26, 2026
- Leqembi Iqlik Now Available for Alzheimer’s Initiation Use in US
August 25, 2026
- FDA Puts Regenxbio’s MPS II Gene Therapy Back on Clinical Hold
August 25, 2026
- Toho Builds Alternative Drug Delivery Options for Disaster Readiness
August 25, 2026
- OB/GYN Sees Abrysvo Becoming Part of Prenatal Care as NIP Drives Uptake
August 25, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…





